Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
papain + urea
- Development stage
- Phase 2
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Debrivoid (papain + urea) is a topical enzymatic debriding ointment used to clean skin wounds by removing dead, damaged, and necrotic tissue. It contains papain, a proteolytic enzyme derived from papaya latex that digests non-viable proteins, and urea, a keratolytic and hydrating agent that softens and denatures proteins to enhance enzymatic action. Developed by Centaur Pharmaceuticals, Debrivoid is indicated for the treatment of chronic skin ulcers (including diabetic foot ulcers, pressure sores, and varicose ulcers), severe burns, and postoperative wounds.
- Brand names
- Debrivoid
- Other names
- papain-ureapapain-urea topicalurea + papain
02
Targets
PEP (Pepsin)
Beyond the preview
Go deeper on papain + urea.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on papain + urea.